AI prediction tool for heart procedures with ITP
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy clinical trials.
This study is testing an AI tool that may help predict how patients with both immune thrombocytopenia (ITP) and coronary artery disease will do after heart procedures. Taking part could help doctors better personalize your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with immune thrombocytopenia (ITP) — a condition of low blood platelet levels that help your blood clot.
- You must have been diagnosed with coronary artery disease (narrowing of the heart's blood vessels) through a test called a coronary angiogram.
- Your ITP diagnosis must have come before your coronary artery disease diagnosis.
- You must not have another cause for low platelets (like certain medicines, blood cancers, or liver disease).
- You must not need long-term blood-thinning medications (for example, for atrial fibrillation or a mechanical heart valve).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
This study looks at whether certain antibodies and small particles in your blood can help doctors identify patients with ITP who are at risk for blood clots. It aims to improve diagnosis and prevention of clotting issues.
This trial tests a combination of two medications—one that targets specific immune cells (CD20 antibody) and one that blocks a key enzyme in those cells (BTK inhibitor)—for people with ITP or AIHA that hasn't improved after standard treatments. The goal is to see if this combination can help control the disease and reduce symptoms.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
This trial tests a medicine called ATRA (a form of vitamin A) to see if it can help adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing bleeding and bruising. It is for people who have already tried standard treatments without lasting success.
Hear when a new Immune Thrombocytopenic Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.